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Abstract
Background
There is limited evidence on the costs of Endometrial Cancer (EC) by stage of disease. We
estimated the long-term secondary care costs of EC according to stage at diagnosis in an
English population-based cohort.
Methods
Women participating in UKCTOCS and diagnosed with EC following enrolment (2001–
2005) and prior to 31st Dec 2009 were identified to have EC through multiple sources. Sur-
vival was calculated through data linkage to death registry. Costs estimates were derived
from hospital records accessed from Hospital Episode Statistics (HES) with additional
patient level covariates derived from case notes and patient questionnaires. Missing and
censored data was imputed using Multiple Imputation. Regression analysis of cost and sur-
vival was undertaken.
Results
491 of 641 women with EC were included. Five year total costs were strongly dependent on
stage, ranging from £9,475 (diagnosis at stage IA/IB) to £26,080 (diagnosis at stage III).
Stage, grade and BMI were the strongest predictors of costs. The majority of costs for
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stage I/II EC were incurred in the first six months after diagnosis while for stage III / IV con-
siderable costs accrued after the first six months.
Conclusions
In addition to survival advantages, there are significant cost savings if patients with EC are
detected earlier.
Introduction
Endometrial cancer (EC) is the most common gynaecologicalmalignancy. The age standard-
ised incidence in the UK has risen from 13.4 to 19.1 per 100,000 over the period from 1998 to
2009,[1] possibly as a consequence of rise in obesity, a known risk factor.[2] Age standardised
mortality from EC has risen from 3.0 to 4.0 per 100,000 over the same period (1999 to 2012).
[3] Women with EC usually present with postmenopausal bleeding and are diagnosedwith
early stage disease. Although five year survival is in excess of 90% in early stage, it declines
sharply to 14% for those with Stage IV disease, similar to ovarian cancer patients.[4] Treatment
is primarily surgical, but varies according to stage with hysterectomy and bilateral salpingo-
oophorectomy (BSO) performed in women detected at Stage I, whilst for women with stage III
and IV disease, chemotherapy or radiotherapy are recommended. The value of lymphadenect-
omy in the treatment of EC is not universally established.[5]
Understanding the costs of treating cancer, and how they vary by stage, is essential to quan-
tify the gains from earlier detection and allow cost-effectiveness analysis of screening pro-
grammes. Costs generally increase with stage but the pattern varies across cancers. Costs of
cervical cancer treatment in the UK increase rapidly from pre-invasive carcinoma (£386)
through stage I (£6,623) to plateau from stages II to IV (£10,910 to £11,035).[6] Costs of breast
cancer (£1991) are flat across stages I to III (£3,576, £3,996, £3,916), rising sharply to £6,590 for
stage IV.[7] Data from the US indicates costs are lowest for stage IV for Colon and Rectal can-
cers.[8–9] Comparable data on EC is limited. A number of studies have examined the cost-
effectiveness of treatment for EC.[10–14] However, these studies typically exploit short term
cost data, and are often based on clinical trials with narrow inclusion criteria. Observational
studies can provide data with longer follow-up that is representative of the patient population
and routine practice. However, the available, observational literature on the cost of EC is based
on records of patients undergoing hysterectomy (potentially excluding some late stage
patients) with limited follow-up and no data on costs by stage.[15–22]
In this paper we evaluate the cost of long termmanagement (diagnosis and treatment) and
survival over five years of a population based cohort of EC patients that is broadly representa-
tive of the UK patient population and routine treatment practice. The patients were partici-
pants in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), one of the
largest multi-centre randomised controlled trials with follow-up through data linkage for can-
cer registrations and deaths.[23] The latter allowed us to identify women diagnosedwith EC
and calculate survival while linkage of participants resident in England to routine administra-
tive hospital data (Hospital Episode Statistics) allowed estimation of management costs of
these patients. Additional patient level covariates, derived from case note review and patient
questionnaires allowed estimation of impact on costs and survival of patient and tumour
characteristics.
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Methods
UKCTOCS was approved by the UK North-West Multicentre Research Ethics Committee
(International Standard RandomisedControlled Trial, number ISRCTN22488978; Clinical-
Trials.gov NCT00058032). Approval for the current analysis was obtained from the Joint UCL/
UCLH Ethics Committee on the Ethics of Human Research (Committee A), Ref: 07/H0714/81,
ethical approval granted on 11th April 2013).
The main trial design, including details of recruitment and screening techniques has been
detailed elsewhere.[23,24] In brief therefore, over 1.2 million women aged 50–74 in the UK
were invited to be screened for ovarian cancer. Over 200,000 women were recruited between
April 2001 and October 2005 through 13 centres in England,Wales and Northern Ireland.
Women completed a recruitment questionnaire and provided written consent to use of their
data in secondary studies. They were randomised to control (no intervention) or annual
screening using either serumCA125 or transvaginal ultrasound (TVS) based strategy. All par-
ticipants were followed up using their National Health Service (NHS) number through the
appropriate national agencies for cancer registrations/deaths as well as by postal question-
naires. The most recent cancer registrations for this analysis were received fromHealth and
Social Care Information Centre (HSCIC) on 17th June 2014.
Women were also linked to their Hospital Episode Statistics (HES) records that were avail-
able for the period 1st April 2001 to 31st March 2010 for participants treated in the English
NHS. HES is an electronic administrative database funded by the NHS which holds records on
both inpatient and outpatient procedures for patients resident in England.[25]
Population and data
The study population consisted of all women resident in England, enrolled in UKCTOCS, who
were diagnosedwith EC betweenApril 2001 and December 2009, and for whomHES records
were available. Patients with a concurrent diagnosis (synchronous) of primary peritoneal or
ovarian cancer in addition to primary endometrial cancer, missing stage or incomplete HES
data (possibly due to patients transferring their care outside the English NHS) were excluded.
The notification of EC diagnosis was received frommultiple sources, the cancer registries
(through the Health and Social Care Information Centre (HSCIC) and HES (Hospital Episode
Statistics) which were searched using the ICD-10 codes of C54 (malignant neoplasm of corpus
uterus) and C55 (malignant neoplasm of uterus, part unspecified), from self-reporting on the
postal follow-up questionnaire or direct contact from the volunteer or their physician. Hospital
records which included surgical and pathological reports were retrieved and independently
reviewed by a clinician using an Outcomes Review form who confirmedEC diagnosis, stage
using the FIGO classification,[26] grade and histological subtype.
UKCTOCS trial data provided patient characteristics including date of birth, BodyMass
Index (BMI) collected at recruitment, hospital records of women diagnosedwith EC and date
of death. For confidentiality reasons only the month and year was available for the date of birth
and date of death; each entry was arbitrarily assigned to the 15th of the relevant month.
HES provided date of admission, date of transfer or discharge, diagnosis (as ICD-10 codes),
[27] procedures undertaken (coded using the Office of Population Censuses and Surveys
(OPCS) Classification of Surgical Operations version 4 codes),[28] treatment specialty, Health-
care Resource Group (HRG)[29] codes for reimbursement, and patient deprivation (measured
as the Index of Multiple Deprivation (IMD) which is a geographically determined index based
on areas of approximately 1500 people).[30]
We included all HES inpatient and outpatient episodes related to EC. Assignment for inpa-
tient procedures was based primarily on OPCS-4 procedure codes taking into account the
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HRG code and treatment speciality. Outpatient records were less complete and procedure
codes were rarely available. Outpatient records lacking procedure codes were only included
where the fields coding the main specialty or the treatment speciality contained a code relating
to either oncology or gynaecology. Investigations occurringwithin six months prior to diagno-
sis were included. Procedures were further classified into surgery (hysterectomy, BSO and pre-
surgical investigations), adjuvant therapy, and further treatment (including management of
complications).
Estimating costs of inpatient and outpatient episodes
Costs were assigned to episodes of care on the basis of the associatedHRG code.[29] This is a
type of Diagnosis Related Groups (DRG) used to assign a reimbursement tariff in the English
NHS. Version (3.5) was used, which allowed assignment of the 2005 Payment by Results (PbR)
tariff to episodes from the entire period 2001 to 2010.[31] We then inflated the cost to 2012/13
prices using the Hospital & Community Health Services Index.[32] Finally we multiplied each
cost by 1.08 which is the average Market Forces Factor for Hospitals in the English NHS.[33]
Market Forces Factors are applied to payments generated fromHRG codes to adjust payments
for unavoidable differences in costs relating to the geographic location of each hospital.[34]
In addition to estimating cost on the basis of HRG code we adjusted costs for extended
length of stay. A maximum length of stay is specified for each HRG code and length of stay
beyond this point is reimbursed at a daily tariff specific to that HRG.Where patient length of
stay during a spell in hospital exceeded the maximum specified for the HRG code we applied
the appropriate excess bed day adjustment to the estimated cost.
PbR tariffs distinguish inpatient and outpatient procedures, and (for inpatient procedures)
elective versus emergency admissions. We assumed that all inpatient admissions were elective
procedures as we lacked data on the type of inpatient admission. Hospital admissions are
remunerated per spell (from admission to discharge). Generally a spell consists of one episode
of care, but occasionally it may consist of more than one episode. In the latter situation hospi-
tals are remunerated according to the dominant procedure for the component episodes (typi-
cally the most expensive).We applied the costs for the most expensive episode for spells of care
consisting of multiple episodes.
Inpatient episodes with missing HRG code (20%) were assigned a code on the basis of
OPCS procedure codes. The majority of outpatient episodes had no HRG or OPCS code
assigned.We identified records of chemotherapy and radiotherapy on the basis of the interval
between admissions and the assigned treatment specialty (medical or clinical oncology). These
records were assigned the appropriate outpatient PbR tariff for radiology or chemotherapy.
The remaining outpatient episodes were assigned the average outpatient cost for 2012/13 of
£135 per episode.[32]
Censoring of cost data
We had missing cost data in the form of censored observationswhere five year follow-up date
and date of death exceeded 31st March 2010 (data available fromHES).We had furthermissing
data on histological subtype (0.4%), grade (3.2%), IMD (0.4%), and BMI (0.8%). IMD scores
were used to partition patients into quintiles.We applied a binary classification of histological
subtype which grouped Atypical Endometrial Hyperplasia (AEH) and Endometrioid EC versus
all other EC histological subtypes.We usedmultiple Imputation (MI) to impute the missing
data.[35] MI is a principled approach which fully captures the additional uncertainty generated
in the imputation process.[36–37] Further details on the application of MI are provided in the
supporting information (S1 File).
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Analysis of cost data
Costs arising in years following the first year after diagnosis were discounted at 3.5% according
to recommendations on technology assessment by the National Institute of Health and Care
Excellence (NICE).[38] FIGO stage was specified as follows: stages IA & IB; stage IC; stage II;
stage III; stage IV. We subdivided costs into three categories: surgery; adjuvant therapy and fur-
ther treatment as detailed above. Costs accumulated at two years after diagnosis are reported
for the subset of patients with a minimum of two years follow-up in HES (diagnosis prior to
31st March 2008). Total costs (after imputation of missing data) were determined for all
patients at five years from diagnosis, with non-parametric 95% confidence intervals estimated
from 1,000 bootstrap replicates of the data (details in appendix). Costs accumulated at five
years after diagnosis for patients with complete cost data (diagnosis prior to 31st March 2005)
are provided in the supplementary material (Table A in S1 File).
Regressionmodelling was undertaken to explore the impact of patient characteristics on
cost. We fitted Ordinary Least Squares (OLS) regression models to each of the three cost cate-
gories and to total costs. We pre-specified the following covariates: age, year of diagnosis, histo-
logical subtype (as Endometrioid Carcinoma/AEH or other), grade, stage, IMD quintile,
Charlson score[39] and BMI.We categorised BMI as under 18.5; 18.5 to 30; over 30. Year of
diagnosis was specified as the number of years following the earliest diagnosis date in the sam-
ple (January 2002). Charlson scores were determined from ICD-10 codes recorded for the hys-
terectomy (or the first inpatient procedure following diagnosis in the absence of hysterectomy)
after exclusion of codes for cancer or metastases.
Analysis of survival data
Dates of death were available until June 2014. Deaths were assigned to EC where the original
underlying cause of death was EC (ICD-10 codes C54.0, C54.1). Regressionmodelling was
used to investigate the impact of patient characteristics on survival over the total observation
time considering both all cause and cancer specificmortality. Cox proportional hazards models
were fitted to the data that adjusted for the same covariates selected for the cost analysis
(detailed above). A Therneau and Grambsch test was applied to assess the appropriateness of
an assumption of proportional hazards.[40]
All statistical analysis was undertaken in Stata, version 13.1.[41]
Results
202,638 postmenopausal women aged 50–74 were randomised to UKCTOCS betweenApril
2001 and September 2005. 157,946 of these women were resident in England. Of these women,
after recruitment, notification of endometrial cancer diagnosis between 17th April 2001 and
31st December 2009 was received for 639 women. 148 women were excluded: 48 women on
retrieving the medical notes were reviewed as having either a diagnosis of cancer other than EC
or synchronous cancer of the endometrium and ovary/peritoneum;97 with incomplete HES
data (case notes indicating surgery had been undertaken but no HES records of hysterectomy
or bilateral salpingo-oophorectomy (BSO); and 3 with missing data on stage. Incomplete HES
data possibly arose from patients transferring their care outside the English NHS. The final
cohort included 491 women of whom 479 women had undergone hysterectomy and/or BSO.
The characteristics of the women are presented in Table 1. There was a trend towards
increasing age and decreasing BMI with later stage at diagnosis. However, Charlson score and
deprivation show no discernible trend by stage. As expected, hysterectomy rates fell off sharply
and use of adjuvant therapy increasedwith advancing stage. The last row in Table 1 reports
five year Kaplan-Meier survival estimates by stage. There is a marked decline in 5-year survival
Costs Associated with Endometrial Cancer
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from 94% (95% confidence interval 94.6–93.8%) for patients diagnosedwith stage IA/IB to 0%
(95% confidence interval 25.1% to 0%) for patients diagnosedwith stage IV disease.
Linking to the HES data, there were 1391 inpatient and 6501 outpatient procedures
recorded for the 491 women in the cohort. Table 2 presents costs based on the HES data
according to category and stage estimated at two years after diagnosis for those diagnosed prior
to 31st March 2008. The costs of EC treatment increasedwith stage. Pre-surgical investigations
and surgery costs show little variation for women detected at early stage but rise for patients
with stage III cancers. Costs of adjuvant therapy increase for patients when diagnosed at stage
IC and rise again for patients diagnosed at stage III. Costs of further treatment also rose sharply
with advancing stage. Total costs at five years post diagnosis are also reported for the entire
sample after imputation of missing data (Table 2). Costs are roughly £2,000 higher than those
at two years for patients diagnosedwith AEH or at stage I/II. For patients diagnosed at stage III
or IV costs are around £10,000 higher at five years. This pattern over time is reflected in Fig 1,
which plots the mean cost accumulation over five years per patient diagnosed grouped by stage
at diagnosis. For AEH, stage I and stage II cancers the majority of costs are incurred in the first
six months whereas for stage III and IV cancers considerable costs are accrued after the first six
months.
Table 1. Characteristics of patients in the study according to stage and five year survival.
AEHb Stage IA & IB Stage IC Stage II Stage III Stage IV
No. of patients 22 277 88 65 34 5
Mean (SD) age (years) 63.0 (6.2) 64.9 (6.1) 66.6 (5.8) 66.6 (5.5) 66.8 (6.2) 69.4 (3.0)
Most deprived fifth (%) 14% 16% 16% 15% 26% 0%
Charlson score 1 or higher (excl. cancer) (%) 64% 42% 31% 43% 24% 20%
Mean (SD) BMI (kg/m2) 29.6 (7.0) 29.4 (6.5) 28.9 (5.1) 28.5 (6.2) 28.3 (5.7) 27.2 (2.7)
Proportion undergoing hysterectomy (%) 91% 100% 99% 98% 94% 20%
Proportion receiving adjuvant therapy (%) 5% 9% 45% 52% 71% 80%
Survival at five years (%)a 95% 94% 89% 81% 56% 0%
aKaplan-Meier estimate; SD standard deviation
bAtypical Endometrial Hyperplasia.
doi:10.1371/journal.pone.0165539.t001
Table 2. Costs of treatment according to stage at two years post diagnosis for patients diagnosed prior to March 31st 2008 and at five years for
all patients after Multiple Imputation of missing data.
Stage Costs by category at two years in 2013 £ for patients with complete cost data
up to two years
Costs by category at five years in 2013 £ for all
patients after imputation of missing data
n Diagnosis/ Surgery Adjuvant therapy Further treatment Total n mean median SDa 95% CI (mean)
AEHb 15 4,760 0 245 5,005 22 7,277 5,835 6,178 5,171–9,369
IA/IB 192 5,555 459 1,507 7,521 277 9,475 7,183 7,567 8,842–12,108
IC 62 5,175 3,069 1,593 9,837 88 11,707 9,117 8,095 10,147–15,546
II 42 5,832 2,953 2,238 11,023 65 13,965 10,185 9,931 12,154–19,793
III 26 7,414 5,581 5,620 18,615 34 26,080 22,342 16,296 18,417–39,062
IV 3 12,843 4,157 0 16,999 5 27,570 24,316 12,501 8,988–67,298
All stages 340 5,691 1,647 1,858 9,197 491 11,705 7,937 9,980 10,919–14,369
aSD standard deviation; CI confidence interval;
bAtypical Endometrial Hyperplasia
doi:10.1371/journal.pone.0165539.t002
Costs Associated with Endometrial Cancer
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Linear regression of costs at two years for patients diagnosed prior to 31st March 2008 indi-
cated increased costs with increasing stage up until stage III (Table 3). Costs for stage IV were
lower than those for stage III but the small number of stage IV cancers limits the generalisabil-
ity of this finding. Grade showed the expected positive relationship with costs, albeit costs for
grade 2 cancers were not significantly higher than costs for grade 1 cancers. There was a trend
to increasing costs with increasing deprivation. Age had no impact on costs but year of
Fig 1. Cost accumulation over time according to stage at diagnosis.
doi:10.1371/journal.pone.0165539.g001
Table 3. Regression analysis of uncensored costs at two years and all costs at five years (after imputation) following EC diagnosis.
Costs at two yearsa Costs at five yearsb
Variable Coeff P-value Coeff P-value
age (centred on 65) 3 0.94 -55 0.44
Charlson score 1 613 0.28 -108 0.90
Charlson score 2 2,482 0.24 2020 0.54
BMI<18.5 -1,141 0.66 736 0.88
BMI>30 -1,310 0.02 -1041 0.22
Stage IA/IB 1,641 0.25 812 0.69
Stage 1C 3,219 0.04 2369 0.30
Stage 2 4,348 0.007 3812 0.11
Stage 3 9,713 <0.0001 13767 <0.0001
Stage 4 8,006 0.017 12002 0.06
diagnosis year 306 0.09 1779 0.17
NS histologyc 539 0.49 407 0.09
Grade 2 418 0.52 920 0.36
Grade 3 3,838 <0.0001 6373 <0.0001
Lowest deprivation -1,137 0.18 -739 0.58
Low deprivation -1,306 0.11 -840 0.51
High deprivation 712 0.40 1709 0.20
Highest deprivation -42 0.96 -387 0.77
constant 4,848 0.003 5793 0.015
Coeff, coefficient; BMI, Body Mass Index.
aCosts at two years analysed for patients diagnosed prior to 31st March 2008
bcosts at five years analysed for all patients.
chistology other than endometrial carcinoma or Atypical Endometrial Hyperplasia
doi:10.1371/journal.pone.0165539.t003
Costs Associated with Endometrial Cancer
PLOS ONE | DOI:10.1371/journal.pone.0165539 November 9, 2016 7 / 13
diagnosis did with costs increasing by £306 (p = 0.09) a year since 2001. Linear regression of
five year costs after imputation of missing data gave similar findings (Table 3). There was some
evidence of lower costs in patients with a BMI>30 at two years deriving predominantly from
reduced adjuvant therapy costs (-£905 for BMI>30, p = 0.013, model not reported). However,
this finding was not confirmed by analysis of five year costs.
Of the 491 women included in the analysis, 61 had died at censorship with 39 having EC as
primary cause of death. Follow-up time for survival ranged from 4.5 to 12.4 years with a
median of 7.4 years. The Cox models for all-cause mortality and for deaths attributed to EC are
presented in the supporting information (Table B in S1 File). In each case, the Therneau and
Grambsch test did not reject an assumption of proportional hazards (p = 0.54). A trend to
increasingmortality with increasing deprivation was observed after controlling for other
patient characteristics for both all cause and cancer specificmortality. Stage, grade and histo-
logical subtype also exhibited the expected relationship. There was a significant reduction in
all-cause and cancer specificmortality over the period analysed. In contrast, there was no dis-
cernible impact of BMI on mortality.
Discussion
Main findings
This is the first study that we are aware of that demonstrates increasing cost of treatment for
EC in women diagnosedwith advanced stage disease.We show that treatment costs are nearly
three times as high for cancers detected at stage III compared to stage IA or IB with majority of
costs for stage I / II EC incurred in the first six months after diagnosis whereas for stage III / IV
considerable costs accrued after the first six months. Consequently, in addition to survival
advantages there are significant cost savings if patients with EC were detected earlier. The dif-
ferences in cost arise from the increased need for adjuvant therapy and increased costs of com-
plications and follow-up procedures in patients diagnosedwith advanced stage disease. These
findings are important in the consideration of the cost-effectiveness of screening for EC.
Strengths and limitations
Our study reported on ECmanagement costs of a population based cohort of women partici-
pating in an ovarian cancer screening trial. The women are therefore more representative of
those in the general population than a hospital based series. Data on treatments is drawn from
a large administrative database representing clinical practice across the NHS in England, rather
than any particular trial protocol. Data collected in UKCTOCS allowed access to independently
reviewed stage, grade and histological subtype at diagnosis, and BMI for each woman alongside
data on deprivation and comorbidities captured fromHES. As a result we were able to explore
the patient and tumour characteristics that have been shown to influence survival, and might
be expected to influence cost.
Whilst resource use data from administrative databases is deemed to be representative of
clinical practice, this source is subject to some limitations. HES only collects data on women
treated by the NHS in England; women opting for privately funded treatments and those
undergoing treatment in hospitals inWales and Scotland would not have those treatments cap-
tured in HES. As a result, we observed incomplete data for 16% of women who we knew from
hospital note review had surgery and had to exclude them from the analysis. Research has
shown that the quality of data capture in HES is good, but it is unlikely to match that of a clini-
cal trial [42–43]. Moreover, it is likely that not all treatments related to EC were captured and
this will have resulted in underestimation of costs. It is possible that the rise in cost over the
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period 2002–2010 observed in the regression analysis reflects improvements in data capture in
HES rather than changes in treatment protocols.
The cost estimates presented here are based on a macro-costing approach in which costs are
assigned to the dominant procedure for a spell in hospital. We were able to adjust costs for
excessive length of stay in hospital but we did not adjust costs for any other variation in treat-
ments. This approach is the recommended approach for costing HES in a recent comparison
of methods [44] and represents the way in which hospitals in the NHS are remunerated.
The available HES data was to the period ending 31st March 2010 and consequently we did
not have complete data on all women in the cohort. This is a common problem in assessing
longer term costs of illness. Various methods have been developed to adjust for censoring in
cost data and recover unbiased estimates of total cost [45–47]. We used a principled approach
which has previously been applied to missing cost data [35,48]. Use of MI allowed regression
analysis of total cost with appropriate consideration of the additional uncertainty introduced
by imputation, and also allowed us to incorporate additional data on mortality (available until
June 2014), an important predictor of cost.
Our analysis did not include the costs of primary care visits and referrals/all investigations
as our study was limited to HES data. We did however cost all investigations documented in
HES as occurring in the six months prior to diagnosis.We limited cost analysis to the five year
period following diagnosis. It is possible that this underestimates costs for patients diagnosed
at stages II and III who die of the disease after five years. The cost data presented here describe
treatment related to EC, the impact of EC on unrelated medical costs has not been quantified
[49]. We would expect this impact to be negative (cost saving) in as far as EC reduces the life
expectancy of women and hence their potential to consume unrelated medical care. Finally,
our analysis did not consider quality of life. Earlier diagnosis and treatment may lead to
improved quality of life as well as survival.
Interpretation
Previous studies on the cost of management of EC are predominantly from the US and have
reported hospital costs for hysterectomy [15–22]. Costs range from $3790 (possibly $1996)16
to $36,487 (possibly $2011) [19]. Data on stage in these studies is frequently unavailable and
none report costs by stage. Further limitations include short follow-up, and the use of hysterec-
tomy to identify patients, which is likely to lead to under representation of patients with late
stage disease. Our study benefitted from use of a population based cohort of EC patients, thus
avoiding selection bias, detailed data on patient and tumour characteristics and long term fol-
low-up. The cost gradient across stages is larger. The findings are important for future assess-
ment of the cost-effectiveness of screening interventions. They indicate the potential for
significant reduction in costs through earlier detection and down-staging particularly from
stage III/IV to stage I/II. This is particularly relevant in view of the recent data fromUKCTOCS
indicating a possible reduction of ovarian cancer mortality with screening [50]. Should this
reduction be confirmed on further follow up, the cost-effectiveness of ovarian cancer screening
will be a driving factor in implementing a national screening programme. Although endome-
trial cancer screening in the general population is currently not warranted [51], earlier detec-
tion may be achieved within an ovarian cancer screening programme and therefore lead to
lower costs of EC treatment.
We found a modest increase in mortality associated with lower socio-economic status, a
finding in line with the broader literature on cancer survival [52,53]. In contrast to some
reports from the US [54,55] we found a modest increase in resource use with increasing depri-
vation, which suggests that any mortality difference do not arise from access to treatment. Our
Costs Associated with Endometrial Cancer
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study had the advantage of access to patient data on BMI and comorbidities, allowing us to
control for these potential confounders. It is possible that some deaths in women with EC were
wrongly attributed to cancer and our observations are attributable to elevated non-cancer mor-
tality in deprived populations which has been previously reported in the UKCTOCS cohort
[56].
Conclusions
The cost of treating EC is strongly influenced by the stage at diagnosis and period of follow-up.
Treatment costs for patients diagnosed at stage III or IV are nearly three times as high as those
of patients diagnosed at stage I with a considerable proportion accruing 6 months post diagno-
sis. In addition to a survival benefit, there are considerable additional resource savings from
diagnosing EC at an early stage, which is an important factor for assessing cost-effectiveness of
EC screening.
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